A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis

Matthew C. Sinton, Jose Meseguer-Ripolles, Baltasar Lucendo-Villarin, ..., Daniel A. Tennant, David C. Hay, Amanda J. Drake
davehay@talktalk.net (D.C.H.) mandy.drake@ed.ac.uk (A.J.D.)

HIGHLIGHTS
LPO-exposed hPSC-derived hepatocyte-like cells resemble human hepatic steatosis
Steatosis is associated with decreased mitochondrial maximal respiration
Purine nucleotide cycle activity increases in steatotic hepatocytes
Excess fumarate production is associated with induction of macrovesicular steatosis
A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis

Matthew C. Sinton,1 Jose Meseguer-Ripolles,2 Baltasar Lucendo-Villarin,2 Sara Wernig-Zorc,3 John P. Thomson,4 Roderick N. Carter,1 Marcus J. Lyall,1 Paul D. Walker,5 Alpesh Thakker,5 Richard R. Meehan,4 Gareth G. Lavery,5 Nicholas M. Morton,1 Christian Ludwig,5 Daniel A. Tennant,6 David C. Hay,2,6,* and Amanda J. Drake1,*

Summary
Nonalcoholic fatty liver disease (NAFLD) is currently the most prevalent form of liver disease worldwide. This term encompasses a spectrum of pathologies, from benign hepatic steatosis to non-alcoholic steatohepatitis, which have, to date, been challenging to model in the laboratory setting. Here, we present a human pluripotent stem cell (hPSC)-derived model of hepatic steatosis, which overcomes inherent challenges of current models and provides insights into the metabolic rewiring associated with steatosis. Following induction of macrovesicular steatosis in hepatocyte-like cells using lactate, pyruvate, and octanoate (LPO), respirometry and transcriptomic analyses revealed compromised electron transport chain activity. 13C isotopic tracing studies revealed enhanced TCA cycle anaplerosis, with concomitant development of a compensatory purine nucleotide cycle shunt leading to excess generation of fumarate. This model of hepatic steatosis is reproducible, scalable, and overcomes the challenges of studying mitochondrial metabolism in currently available models.

Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common form of hepatic disease and is strongly associated with obesity and type 2 diabetes (WHO, 2006). In the earliest stage of NAFLD, triglyceride (TG) accumulation in hepatocytes leads to the development of hepatic steatosis (Valenti et al., 2016). This is characterized by the development of macrovesicular steatosis, with TG storage in large lipid droplets (Wang and Yu, 2016). Although steatosis is largely benign, it can progress to nonalcoholic steatohepatitis (NASH), which, in turn, increases the risk of developing cirrhosis and hepatocellular carcinoma (Asrih and Jornayvaz, 2015). However, the mechanism(s) underlying this progression have yet to be determined. At present, there are no specific therapeutics available to reverse or treat NAFLD, and the only effective intervention is through the reduction of obesity through diet and exercise or following bariatric surgery (Laursen et al., 2019).

In order to understand the pathophysiology of the NAFLD disease spectrum, studies have been undertaken in rodent models, in vitro culture systems, and human liver biopsy samples. Dietary intervention or genetic manipulation leading to the development of obesity and/or hepatic steatosis in rodents often fails to fully recapitulate the NAFLD phenotype. For example, although the leptin-deficient Ob/Ob mouse develops extreme obesity and metabolic abnormalities, the profound abnormalities in circulating leptin mean that this model is not representative of human disease in the general population (Anstee and Goldin, 2006; Rotundo et al., 2018). Likewise, dietary interventions mimic specific stages of NAFLD, such as steatosis or inflammation, but do not reflect the disease progression that occurs in humans (Oligschlaeger and Shiri-Sverdlov, 2020). A common dietary intervention is the methyl-donor-deficient (MDD) diet, which recapitulates the inflammatory responses associated with NASH but not the other elements of the metabolic syndrome (Lyall et al., 2017; Rinella and Green, 2004). In vitro approaches commonly utilize immortalized cell lines derived from hepatocellular carcinoma; however, malignant transformation is known to induce profound changes in metabolic phenotype (Huang et al., 2013; Pavlova and Thompson, 2016), limiting their utility for modeling NAFLD metabolism. Using whole liver tissue from rodent models or humans to study
metabolism in distinct cell populations necessitates disaggregation and sorting, a process that induces oxidative stress, potentially confounding analyses (Llufrio et al., 2018). Analysis of primary cells may also be confounded by the cell sorting process (Llufrio et al., 2018).

In terms of mechanisms, studies in animal models and humans have shown that NAFLD is associated with mitochondrial dysfunction including altered electron transport chain (ETC) activity (Koliaki et al., 2015; Rector et al., 2010), altered tricarboxylic acid (TCA) cycle activity and anaerobiosis (Satapati et al., 2012; Sunny et al., 2011), induced oxidative metabolism, with a proportional increase in oxidative stress (Satapati et al., 2015) and changes in mitochondrial respiration (Koliaki et al., 2015). In these studies, the presence of multiple cell types in tissue samples may confound the results, and this is further complicated by the changes in cell proportions that may occur in disease states.

Here, we present a human-relevant model of hepatic steatosis that can be used for high-resolution analysis of metabolic function and that may provide novel insights into human NAFLD. We hypothesized that nutrient excess in NAFLD leads to increases in ETC activity due to increased availability of respiratory substrates. We aimed to determine the impact of lipid accumulation on mitochondrial respiration specifically in hepatocytes, to avoid the confounding effects associated with bulk tissue analysis.

Results

Lactate, pyruvate, and octanoate treatment induces macrovesicular steatosis in hepatocyte-like cells

We and others have previously reported that the high-energy substrate cocktail LPO promotes intracellular lipid accumulation in pluripotent stem-cell-derived hepatocyte-like cells (HLCs) (Lyall et al., 2018) (schematic of this process is shown in Figure 1A) and human hepatocyte or hepatoblastoma cell lines (Gilchrist et al., 2010; Lockman et al., 2012, 2016). However, it was not known whether LPO promotes lipid droplet biogenesis or increased accumulation of lipids within existing droplets. Stem-cell-derived HLCs were differentiated and characterized by measuring mRNA levels of a marker of pluripotency (NANOG) and markers of hepatocytes (Albumin; ALB and hepatocyte nuclear factor-4-alpha; HNF4A) (Wang et al., 2017) (Figure 1B). CYP3A4 activity was present in control HLCs and those challenged with LPO, demonstrating that they retained hepatocyte function (Figure 1C). Analysis of gene expression using RT-qPCR showed increased expression of transcripts that are typically associated with intracellular lipid droplet membranes: perilipin 2 (PLIN2), PLIN4, and PLIN5, suggesting an increase in lipid droplet size (Figures 1D and 1F). This was supported by analysis of lipid accumulation using high content imaging, which demonstrated that 48 h of LPO exposure was not associated with a change in the number of intracellular lipid droplets (Figure 1G) but led to a ~2-fold increase in their size (Figure 1H), consistent with the development of macrovesicular steatosis.

LPO treatment induces intracellular lipid accumulation and transcriptomic alterations in key mitochondrial respiratory pathways

Induction of steatosis in HLCs was associated with widespread transcriptomic changes (Figure 2A). Differential gene expression analysis identified 853 downregulated and 826 upregulated genes (log2 fold change cut-off >1.5) in LPO exposed cells compared with controls. A selection of candidate genes was validated by RT-qPCR (Figure S1), based on genes that we previously found to be dysregulated in association with steatosis (Lyall et al., 2018). RNA-seq analysis revealed altered expression of a number of genes previously described as having functional roles in the progression of NAFLD, including PLIN2, PPARGC1A, CYP7A1, and HMGC5S2 (Figure 2B). Mapping genes with a log2 fold change >1.5 to the KEGG pathway database identified a number of enriched pathways (Figures 2C and 1D), including those related to steroid hormone biosynthesis (18 genes) and ascorbate and aldarate metabolism (7 genes) (Table S4). There was extensive downregulation of the histone structural units H1, H2A/B, H3, and H4 and UDP-glucuronosyltransferases, which were enriched in multiple pathways. Specifically comparing transcriptomic data with the KEGG terms “TCA cycle” and “oxidative phosphorylation” revealed marked gene expression changes within these pathways (Figures 2E and 2F) including in the majority of genes encoding enzymes that catalyze metabolite interconversion (Table S5). Analysis of the oxidative phosphorylation pathway revealed an overall downregulation of transcription of genes encoding components of respiratory complexes I (ND1, ND2, ND4L, NDUF52, NDUFV1, NDUF4A10, NDUF82, NDUF2, NDUF810, and IV (COX1, COX4I1, COX8A, COX8B1), as well as ATP synthase (ATP6V1A, ATP5MF, ATP6V0D1, ATP6V1E1, ATP6, APT5MC2, ATP5MC1) (Table S6).
Figure 1. LPO treatment induces development of macrovesicular lipid droplets, similar to benign steatosis in humans

(A) Schematic overview showing differentiation process and induction of lipid accumulation.

(B) H9 hPSCs differentiate to HLCs, losing pluripotency as shown by diminished expression of the pluripotency marker NANOG during the differentiation process. Concomitantly, these cells begin expressing the hepatocyte markers albumin (ALB) and hepatocyte nuclear factor-4-alpha (HNF4A) (n = 3 biological replicates/group).

(C) Differentiated HLCs display robust CYP3A4 activity, which is not diminished following challenge with LPO.

(D–F) Perilipin 2 (PLIN2), PLIN4, and PLIN5 expression increases in response to LPO treatment (n = 3 biological replicates per group).

(G) Number of lipid droplets do not increase, but intracellular lipid droplets increase in size (n = 32 biological replicates/group). Data were analyzed using two-tailed Student t test and expressed as mean ± SD, *p < 0.05, ****p < 0.0001.
Figure 2. Steatosis in hepatocytes is associated with transcriptional rewiring reflecting human NAFLD

(A) Heatmap analysis of transcriptional changes associated with macrovesicular steatosis.

(B) Expression of key NAFLD-associated genes is disrupted in steatotic HLCs.

(C–D) Pathway enrichment analysis reveals a number of disrupted pathways associated with macrovesicular steatosis.
Macrovesicular steatosis in hepatocytes is associated with electron transport chain dysfunction

It has been suggested that NAFLD-associated macrovesicular steatosis results in impairment of mitochondrial respiration (Koliaki et al., 2015), and we therefore proceeded to analyze this in steatotic HLCs (Figure 3A). Basal oxygen consumption rate (OCR), representing combined mitochondrial and non-mitochondrial oxygen consumption, was unchanged following LPO exposure (Figure 3B). In addition, oligomycin A, a complex V inhibitor decreased OCR equally effectively in control and treatment group. Firstly, this indicated that there were no changes in ATP-linked respiration in response to macrovesicular steatosis (Figure 3C). Secondly, when comparing oligomycin-A-induced alterations in OCR with those following addition of rotenone/antimycin A, we could detect no changes in proton leak between groups (Figure 3D). The addition of the ETC uncoupler FCCP revealed a decrease in maximal respiration in the steatotic HLCs, suggesting mild ETC dysfunction (Figure 3E). Using OCR measurements following FCCP treatment, and comparing with the basal OCR, we calculated that there was a decrease in reserve capacity in the LPO-treated cells, compared with controls (Figure 3F). Subsequently, complex I and III were targeted with rotenone/antimycin A, to completely inhibit oxidative phosphorylation, which reduced OCR to a similar level in both groups, suggesting no difference in non-mitochondrial sources of OCR between the control and steatotic HLCs.

Induction of macrovesicular steatosis is not associated with altered mitochondrial number or mitochondrial integrity

We wanted to analyze whether changes in ETC function, as demonstrated by decreased cellular maximal respiration and reserve capacity, were due to altered numbers of mitochondria. Because these were the only respiratory measurements to change, we hypothesized that this was not the case. To test this, we used a high-content microscopy-based approach to measure intracellular mitochondrial fluorescence and observed no changes following exposure to LPO (Figure 3G), indicating no change in quantity. We then measured protein levels of succinate dehydrogenase subunit A (SDHA) and pyruvate dehydrogenase (PDH) α1 and α2 subunits (Figure 3H; representative blot Figure S2), which localize to the mitochondria. Protein levels of SDHA and PDH did not change in response to intracellular lipid accumulation. Furthermore, there were no changes in mitochondrial or nuclear DNA (Figure S3) and no change in the ratio of nuclear to mitochondrial DNA (Figure 3I), suggesting that mitochondrial number is not altered by LPO-induced macrovesicular steatosis. To analyze whether the observed changes in OCR could be due to diminished mitochondrial integrity rather than ETC dysfunction, we measured citrate synthase (CS) activity. This has previously been described as a measure of mitochondrial integrity (Boutagy et al., 2015; Short et al., 2005). Our findings suggest that LPO treatment has no marked impact on CS activity (Figure 3J), suggesting that mitochondria remain intact following intracellular lipid accumulation. Taken together, these data demonstrate that mitochondrial number was not altered in response to macrovesicular steatosis. This suggests that the altered respiratory complex activity may arise due to reactive oxygen species (ROS)-mediated dysfunction, rather than changes in protein content, although this requires further investigation.

Induction of an NAFLD-like phenotype in HLCs is associated with increased pyruvate carboxylase activity

To investigate TCA cycle dynamics in HLCs, lactate in the LPO cocktail was replaced with 13C3-lactate. Lactate can enter the TCA cycle via mitochondrial pyruvate metabolism, through either pyruvate carboxylase (PC) or pyruvate dehydrogenase (PDH). Alternatively, pyruvate can be transported into the cytosol and used in gluconeogenesis (Figure 4A). LPO exposure was associated with increases in steady state levels of pyruvate, aspartate, and citrate, but there were no changes in metabolites associated with the gluconeogenesis pathway (Figure 4B). Although pyruvate was added as part of the LPO cocktail, increased pyruvate generation also occurred as a result of increased lactate dehydrogenase activity (Figure 4C). Although we were unable to directly measure oxaloacetate levels, we used aspartate as a surrogate and found increased m+3 labeling, demonstrating direct synthesis of aspartate from pyruvate (Figure 4D). Furthermore, isotopomer labeling of citrate indicated increased incorporation from pyruvate-derived oxaloacetate and decreased conversion of labeled acetyl-CoA by PDH (Figure 4E). An alternative pathway for pyruvate is
Figure 3. LPO treatment results in decreased mitochondrial maximal respiration and reserve capacity, suggestive of respiratory complex impairment.

HLCs were injected sequentially from ports A–C with 4 μM oligomycin, 0.5–1 μM FCCP, and 1 μM antimycin combined with 200 nM rotenone. (A) Raw trace of OCR comparing cells with or without LPO treatment; (B) basal respiration (C) ATP-linked respiration and (D) proton leak were unchanged in LPO-treated HLCs. In contrast, maximal respiration (E) and reserve capacity (F) were both diminished following LPO treatment (n = 18 and 16 biological replicates in the control and treatment group, respectively, from two plates). (G) High-content microscopy revealed no changes in fluorescence of mitochondrial in response to treatment (n = 4 and 6 biological replicates in the control and treatment group, respectively). Representative images of mitochondrial content in control and LPO-treated groups 10x magnification. Blue staining = NucBlue, red staining = MitoTracker Deep Red. Scale bar: 25 μm. (H) There were no changes in abundance of the mitochondrial proteins succinate dehydrogenase subunit (SDHA) or pyruvate dehydrogenase α1 and α2 subunits (PDH) (n = 6 biological replicates/group). (I) There were no significant changes in the ratio of mitochondrial to genomic DNA, when comparing mitochondrial region 2 (MT2); mitochondrial region 3 (MT3); or genomic region beta-globin (HBB), indicating no alterations in the quantity of mitochondria in response to treatment (n = 4 biological replicates/group). Levels of citrate synthase activity appears unaltered by LPO treatment (n = 3 biological replicates/group). Data were analyzed using two-tailed Student t test for parametric data, or Mann-Whitney U test (D, I) for non-parametric data, and expressed as mean ± SD.
conversion to alanine, and although there were no changes in steady state alanine levels, there were moderate, but significant, changes in the incorporation of $^{13}$C (Figure 4F), indicating overall transamination of pyruvate toward alanine. Despite there being no increase in steady state levels of gluconeogenesis-associated metabolites, the increased m+2 labeling of 3-PG (Figure 4G), serine (Figure 4H), and glycine (Figure 4I) suggests increased flux through the gluconeogenesis pathway.

Steatosis in HLCs is associated with increased TCA cycle anaplerosis

Isotopic labeling of TCA metabolites can produce a number of different isotopomers, depending on the directionality of metabolite synthesis (Figure 5A). In steatotic HLCs, we observed increases in steady state

Figure 4. Macroversicular steatosis is associated with increased PC activity, leading to preferential anaplerosis of pyruvate into the TCA cycle

(A) Schematic outlining conversion of lactate to pyruvate and routes by which this can be converted. Black circles denote carbon atoms.
(B) Steady state measurements of pyruvate and metabolites that pyruvate can be converted into. Isotopomer labeling patterns of pyruvate (C), aspartate (D), and citrate (E) show anaplerosis into the TCA cycle. There is minimal conversion of pyruvate to alanine (F–G), but increased flux of the m+2 isotopomer through metabolites related to gluconeogenesis, with sustained conversion to 3-PG, serine, and glycine (H–K). For NMR data, labels are: 1 = $^{13}$C labeling, 0 = no $^{13}$C labeling. All GC-MS data consisted of 10 biological replicates and 2 technical replicates. Isotopomer data were calculated by multiplying MID (multiple ion detection) by normalized total ion count. For NMR data (G and K) n = 4 biological replicates/group. Data were analyzed by two-way ANOVA with Sidak post-hoc testing, or (I–J) two-tailed Student’s t test. Data are expressed as mean ± SD.
levels of the TCA cycle metabolites αKG, fumarate, and malate (Figure 5B). In contrast, there were no changes in the steady state levels of succinate and no evidence for increased metabolism of glutamate.

To further analyze alterations in TCA cycle dynamics we measured 13C incorporation into metabolites. Although there was increased 13C incorporation into PC-derived citrate (Figure 4E), this was not the case for αKG (Figure 5C). The decreased levels of 13C incorporation into glutamate suggests that this does not result from increased cataplerosis through glutamate (Figure 5D). The increased expression of OGDHL and decreased expression of SUCG1 (Table S5) suggest that steatosis may be associated with
metabolic reprogramming within the mitochondrial matrix supported by altered protein synthesis. Although decreased incorporation of $^{13}$C into succinate was observed (Figure 5E), a parallel increase in $^{13}$C incorporation into fumarate, malate, and aspartate was also apparent (Figures 5F and 5G). Because the overall directionality of the malate dehydrogenase and fumarate hydratase reactions can vary depending on the metabolic environment (Dasika et al., 2015; Tyrakis et al., 2017), increased incorporation of $^{13}$C into both malate and fumarate indicate increased overall flux of carbons into these metabolites from the oxaloacetate pool. Taken together, this suggests dysregulated TCA cycle flux in steatotic cells, which may be associated with changes in SDH activity (Figure 5H). The increased incorporation of $^{13}$C into oxaloacetate (using aspartate as a surrogate) demonstrates increased PC activity, driving the conversion of pyruvate to oxaloacetate and suggests possible disruption of associated metabolic cycles, including the malate-aspartate shuttle (MAS) and the purine nucleotide cycle (PNC).

**Increased PNC and MAS activity drives NAFLD-associated fumarate accumulation**

Next, we wanted to determine the source of fumarate accumulation in steatotic HLCs. Transcriptomic analysis identified dysregulation of multiple genes associated with the MAS (Figure 6A) and PNC (Figure 6B), indicating that these pathways may be involved in fumarate accumulation. To investigate this further, HLCs incubated with $^{13}$C-labeled LPO were co-incubated with either 5-Aminoimidazole-4-carboxamide-1-b-D-ribofuranosyl 5’-monophosphate (AICAR) or O-(Carboxymethyl)hydroxylamine hemihydrochloride (AOA) to inhibit the PNC or MAS, respectively. Addition of AICAR increased only the steady state levels of $\alpha$KG, and neither AICAR nor AOA had a significant impact on the synthesis of pyruvate, citrate, succinate, or malate (Figure 6C). However, both inhibitors significantly reduced steady state levels of fumarate and aspartate. Although addition of AICAR did not impact on the synthesis of PDH-derived citrate (Figure 6D), it did result in increased accumulation of PDH-derived $^{13}$C in $\alpha$KG (Figure 6E), suggesting impaired conversion to succinyl-CoA or increased anaplerosis from glutamate. AICAR was also able to partially restore the effects of steatosis on succinate levels (Figure 6F), resulting in small but significant increases in PC- and PDH-derived isotopomers. The most profound effect of AICAR was on fumarate, with each isotopomer reduced to levels below those observed in the control group (Figure 6G), suggesting that in steatotic HLCs, fumarate accumulation is primarily driven by the PNC. Following AOA treatment, we observed a moderate decrease in PC-derived $^{13}$C incorporation into fumarate, demonstrating a small contribution from the MAS. AICAR had a moderate impact on incorporation of PC-derived incorporation of $^{13}$C into malate, whereas AOA impacted on both PC- and PDH-derived $^{13}$C incorporation, suggesting limited contribution of the MAS and PNC to malate accumulation (Figure 6H). Both AICAR and AOA reduced incorporation of $^{13}$C into aspartate (Figure 6I). These data show that the metabolic consequences of LPO treatment, likely driven by increased TCA cycle anaplerosis through OAA, include an increase in both MAS and PNC activity (Figure 6J).

**Inhibition of fumarate accumulation inhibits lipid droplet hypertrophy in LPO-treated HLCs**

To determine whether manipulation of fumarate levels affected the development of macrovesicular steatosis, we performed HCA microscopy on HLCs. Cells were treated with LPO in the presence or absence of AICAR. Cells that received AICAR did not develop macrovesicular steatosis (Figure 6K). These results were corroborated by the addition of exogenous fumarate to steatotic HLCs treated with AICAR, which resulted in the development of larger lipid droplets.

**Fumarate accumulation is not associated with widescale alterations of 5hmC in protein-coding regions in steatotic HLCs**

One potential consequence of fumarate accumulation in steatotic HLCs is inhibition of $\alpha$KG-dependent dioxygenase enzyme activity. Given our previous data showing altered ShmC in a mouse model of NAFLD and the potential importance of the TET enzymes in hepatocellular carcinoma (Lyall et al., 2020; Thomson et al., 2016), we used a DIP-seq approach to measure changes in ShmC across the genome. Within each group, samples were highly correlated, suggesting that the ShmC patterns are stable between replicate samples (Figure 7A). We identified 3,294 differentially hydroxymethylated regions (DHRs) between LPO exposed and control cells (>2-fold change, see methods), with the majority of changes located in intragenic or intronic regions (Figure 7B). ShmC in gene body regions may functionally relate to mRNA transcription (Thomson et al., 2016), and we therefore generated heatmaps representing mean changes across the gene body, with cluster 1 showing subtle increases in ShmC within the TSS region (Figure 7C). Analysis of genic ShmC patterns revealed that a number of promoter regions displayed changes in ShmC levels following LPO exposure (Figure 7D). Integration of DHR and RNA-seq data for promoter regions upstream of the
Figure 6. In the presence of TCA cycle truncation, the purine nucleotide cycle and malate-aspartate shuttle fuel fumarate accumulation

(A and B) Transcriptomic analysis showed increased expression of malate-aspartate shuttle (MAS) and purine nucleotide cycle (PNC) transcripts, indicating perturbed activity.

(C) Inhibition of the PNC and MAS reversed steatosis-induced accumulation of fumarate and aspartate but not malate.

(D–G) (D) PNC inhibition moderately impacted PC-derived citrate $^{13}$C labeling but not (E) αKG or (F) succinate. (G) In contrast, PNC inhibition profoundly reduced incorporation of $^{13}$C into fumarate. MAS inhibition also limited PC-derived fumarate accumulation, but to a lesser extent.

(H) PNC and MAS expression also inhibited generation of PC-derived malate but to a much smaller extent than fumarate.
transcriptional start site revealed 12 promoter regions with differential enrichment of 5hmC (>2-fold) and where mRNA expression was altered >0.5-fold. Linear regression of these regions identified a moderate but significant negative relationship between 5hmC enrichment and mRNA expression (Figure S4; Table S7). Of these genes 7 (EPHX3, ERO1B, CSGALNACT1, DOC2A, COL6A1, CASP1 and TMEM88) were previously shown to be dysregulated in the pathogenesis of NAFLD or progression to cirrhosis (Atanasovska et al., 2017; Cazanave et al., 2017; Parafati et al., 2018; Revill et al., 2013; Wilson and Kumar, 2018). Conversely, to our knowledge, there are no described associations between NAFLD and the remaining genes in this list (DDN, OGFRL1, OCIAD2, ABAT, CCDC150). Our findings may indicate a role for 5hmC in the regulation of these genes in NAFLD pathogenesis.

Discussion
NAFLD is a challenging disease to study in humans. This is due to the difficulty of obtaining tissues that are not compromised by confounding conditions, making high-resolution analysis of transcriptional and metabolic rewiring challenging. In this study we sought to explore the utility of a human-HLC-based model for the study of transcriptomic, epigenomic, and metabolomic dysfunction associated with hepatic steatosis.

Using a combination of high content microscopy and gene expression analyses, we showed that treatment of HLCs with LPO induces intracellular lipid accumulation, recapitulating the macrovesicular steatosis observed in NAFLD (Figure 1G). This was in parallel with changes in the expression of genes associated with lipid droplet size (Figures 1D–1F) and is in agreement with findings from human studies (Fujii et al., 2009; Sahini and Borlak, 2016).

The disruption of the expression of genes in multiple pathways related to metabolism confirms the findings of a number of previous studies in humans and mice (Collison et al., 2009; Hardwick et al., 2013; Kolwankar et al., 2007; Liu et al., 2016; Nikolau et al., 2019; Schröth et al., 2016; Suppli et al., 2019; Yamaguchi and Murata, 2013). Consistent with the altered expression of multiple subunits of respiratory complexes I, IV, and ATPase, respirometry-based analyses revealed decreased maximal mitochondrial respiration and spare capacity (Figures 3E and 3F). Previous data suggest that NAFLD associates with inhibition of respiratory activity in complexes I–III in hepatocytes (Koliaki et al., 2015). Our transcriptomic and metabolomic data suggest that this inhibition most likely occurs in complexes I and II. In terms of mechanisms, octanoic acid inhibits complex I–III in rat liver (Scaini et al., 2012) and excess fumarate may also inhibit complex II activity, although manipulation of fumarate did not alter activity of this complex, suggesting that this is not the case.

We then questioned whether changes in maximal respiration arose from increased biogenesis or from changes in mitochondrial integrity. Our findings suggest that mitochondrial biogenesis was not affected by LPO treatment (Figure 3), because maximal respiration was the only parameter of respiration that changed, and the ratio of nuclear to mitochondrial DNA, as well as HCA microscopy analysis of mitochondrial mass were not altered. In addition, the finding that CS activity was not adversely affected suggests that mitochondrial integrity was not compromised, although this requires further study. These findings are consistent with human studies of NAFLD that show no changes in mitochondrial mass in steatotic liver tissue (Koliaki et al., 2015). In contrast, liver tissue from patients with NASH contains greater numbers of mitochondria and a decrease in maximal respiration, indicating that a transition in mitochondrial function occurs between these two disease states (Koliaki et al., 2015). The reasons for this are unclear; differences in maximal respiration between NAFLD and NASH could reflect impairment of the ETC and/or changes in baseline mitochondrial respiration. In NASH, the decrease in maximal respiration may be a consequence of increased mitochondrial fragmentation and concurrent decreases in

Figure 6. Continued
(I) PNC and MAS inhibition also resulted in a significant reduction in the generation of PC-derived aspartate.
(J) Schematic outlining of the proposed pathways by which fumarate accumulation occurs in response to steatosis.
(K) Inhibition of fumarate through the PNC reduced LPO-induced macrovesicular steatosis, which was partially restored through addition of exogenous monomethyl fumarate. For NMR data, labels are: 1 = 13C labeling, 0 = no 13C labeling. AICAR = PNC inhibitor, AOA = MAS inhibitor. All control and LPO group GC-MS data consisted of 10 biological replicates and 2 technical replicates, as shown in Figure 3. GC-MS LPO + AICAR and LPO + AOA groups consisted of six biological replicates/group. Isotopomer data were calculated by multiplying MID by normalized total ion count. For lipid droplet analysis (K), the LPO group is as shown in Figure 1. For the LPO + AICAR and the LPO + AICAR + Fumarate group, n = 31 and 28 biological replicates/group, respectively. Data were analyzed by two-way ANOVA with Sidak post-hoc testing and are expressed as mean ± SD.
mitophagy (Knott et al., 2008; Koliaki et al., 2015). The differences between studies may also reflect the isolation of mitochondria from the multiple cell types present in whole tissues, which may be altered as a consequence of the disease process. We suggest that the model of hepatic steatosis presented here may mirror the transition between NAFLD and NASH, with respiratory dysfunction in the absence of mitochondrial biogenesis. Future experiments, with longer exposure to LPO and/or the incorporation of non-parenchymal cells into the model, may shed light on this.

In agreement with studies in mouse models, and indirect studies in humans, NAFLD was associated with increased hepatic TCA cycle activity (Figure 5B) (Satapati et al., 2012; Sunny et al., 2011). We identified

---

**Figure 7.** Macrovesicular steatosis in HLCs does not correlate with wide-scale changes in 5hmC enrichment

(A) Correlation heatmap of control versus LPO groups, following hmeDIP sequencing, clustered by Euclidean distance.

(B) Proportion of DHRs associated with different regions of the genome, showing the majority located in intragenic and intronic regions.

(C) Heatmap of DHRs, with an FDR of <0.05 and k-means clustering.

(D) Sliding window analysis of the transcriptional start site (TSS), gene body, and transcriptional end site (TES) shows minimal changes between control and LPO groups. For both control and LPO, n = 3 biological replicates/group.
substantial disruption of TCA cycle and oxidative phosphorylation pathways indicating compromised energy metabolism in steatotic HLCs. As TCA cycle flux generates NADH and FADH₂, which transfer electrons to the electron transport chain (ETC), alterations in TCA cycling may have a direct impact on respiration and oxidative stress. In order to delineate detailed information on TCA cycle flux dynamics we utilized stable isotopic tracing with ¹³C₃-lactate, which provides greater metabolite labeling than other substrates (Hui et al., 2017). In the liver, flux of substrates into the TCA cycle predominantly occurs via PC (Lardy et al., 1965), and there is evidence suggesting that PC activity increases in NAFLD (Sunny et al., 2011) and contributes to increased rates of gluconeogenesis through conversion of oxaloacetate to phosphoenolpyruvate (Satapati et al., 2012). Our data support the assertion that PC activity increases in steatotic HLCs and that pyruvate is predominantly utilized to sustain TCA cycle activity. Although we observed sustained synthesis of gluconeogenesis-associated metabolites in steatotic HLCs, there was no increase in gluconeogenesis-associated metabolites m ay suggest that pyruvate-derived acetyl-CoA is being oxidized to OAA via citrate as a means to enter the gluconeogenic pathway.

Although increased flux of substrates into the TCA cycle leads to higher levels of TCA cycle activity (Sunny et al., 2011), our data suggest that changes in the TCA cycle are more nuanced than was previously suggested, with enhanced anaplerosis from pyruvate/lactate into the TCA cycle and inhibition of the conversion of succinate to fumarate in steatotic cells. This raised the question of what leads to the diminished incorporation of ¹³C into succinate. The decreased cataplerosis through glutamate suggests that this could be due to perturbation of TCA cycle equilibrium, leading to altered interconversion of succinyl-CoA and succinate, which may, in turn, lead to the generation of an increased pool of succinyl-CoA. This is supported by the observation of decreases in PC-derived glutamate and succinate, despite no changes in PC-derived αKG. Because interconversion between succinyl-CoA and succinate is in near equilibrium and readily reversible (Lynn and Guynn, 1978), we propose that this effect could be a result of an alteration in the equilibrium of this reaction, with enhanced succinyl-CoA synthesis, which could be elicited through branched-chain amino acid catabolism.

Despite truncation of the TCA cycle, steatotic HLCs rewire their metabolic circuitry to compensate for this, generating increased levels of fumarate through the PNC, and to a lesser extent the MAS. A similar metabolic bypass has been reported in cardiac ischemia (Chouchani et al., 2014), as well as in human and mouse in vitro models of tumorigenesis (Tyrakis et al., 2017). In ischemic reperfusion injury, increased PNC activity results in fumarate overflow, driving reversal of succinate dehydrogenase activity and accumulation of succinate (Chouchani et al., 2014). We did not observe the same phenomenon here, but rather found evidence for inhibition of succinate dehydrogenase activity in steatotic HLCs. Although fumarate can be generated from reversal of fumarate hydratase (FH) activity (Chouchani et al., 2014), we were unable to directly manipulate the activity of this enzyme in order to assess its contribution to the fumarate pool in steatotic HLCs. However, as FH operates at equilibrium (Ajalla Aleixo et al., 2019) it is possible that PNC-fueled fumarate accumulation prevents reverse catalytic activity. Defects in complex I can lead to a reduction in the levels of NAD⁺ (Porcelli et al., 2010) and regeneration of fumarate via the PNC may be one mechanism of increasing the NADH pool and maintaining the hydrogen ion gradient of the ETC. Our data suggest that fumarate is important for the development of macrovesicular steatosis; inhibition of the PNC prevented development of macrovesicular lipid droplets, and this was partially restored following the addition of exogenous fumarate (Figure 6K). This correlates with findings in oligodendrocytes and C8⁺ T cells, in which exposure to exogenous fumarate resulted in perturbed lipid metabolism (Bhargava et al., 2019; Huang et al., 2015), although the mechanism by which this occurs is unknown.

Fumarate accumulation can impact the activity of the αKG-dependent dioxygenase enzyme family, including the ten-eleven translocation (TET) enzymes, which are involved in the conversion of 5-methylcytosine (5Mc) into 5-hydroxymethylcytosine (ShmC) and subsequent steps in the DNA demethylation pathway (Tahiliani et al., 2009). We have previously shown that the TET enzymes play an important role in the development of hepatocellular carcinoma and that ShmC enrichment is reversibly altered at specific loci in response to hepatic fat accumulation (Lyall et al., 2020; Thomson et al., 2016). ShmC is a stable epigenetic modification and studies suggest that ShmC enrichment at transcriptional start sites (TSSs) associates with transcriptional repression (Wu et al., 2011). We did not observe wide-scale changes in ShmC enrichment, and ShmC changes at specific loci did not, in general, correlate with transcriptional changes in steatotic cells, except at a limited number of promoter regions.
This human-cell-based model displays many of the transcriptional and metabolic characteristics associated with human hepatic steatosis, and we propose it as a useful addition to the field. Although there are a number of current in vitro approaches for the study of steatosis, these often use HCC cell lines, which have perturbed metabolic function arising from the process of malignant transformation and immortalization (Huang et al., 2013; Pavlova and Thompson, 2016). This may limit their utility for studying steatosis-associated metabolic changes in non-malignant cells. Furthermore, culturing of HCC cell lines is associated with loss of 5hmC, making them unsuitable for studying the interplay between mitochondrial metabolism and TET-mediated modulation of the epigenome (Chen et al., 2013; Hernandez-Vargas et al., 2010; Liu et al., 2013; Thomson et al., 2016; Xu et al., 2011). As an alternative, primary mouse and human hepatocytes can be used to model hepatic steatosis, but these cells have a limited lifespan, cannot be passaged or expanded in vitro, and human cells are often isolated from fundamentally abnormal, e.g. fatty livers (Hirsova et al., 2016; Lyall et al., 2018). The process of cell sorting may also confound metabolomic, transcriptomic, and epigenomic analyses in cell lines (Llufrio et al., 2018), and the necessity for both tissue disaggregation and cell sorting, which are needed to enable the study downstream effects in individual cell types from whole tissue biopsies, can make the interpretation of results even more challenging (Llufrio et al., 2018). The model system presented here overcomes many of these challenges, as HLCs display a similar metabolic phenotype to human hepatocytes and cell sorting is not required (Wang et al., 2017). Furthermore, these cells retain 5hmC in patterns similar to those observed in humans (Ivanov et al., 2013), making them well suited to studying the interplay between mitochondrial metabolism and the epigenome.

The system, allowing the study of transcriptomic, epigenomic, metabolomic, and proteomic effects in a single cell type, can be adapted for the analysis of effects induced by a variety of alternative agents that may induce steatosis. In addition, this model system can be scaled up to model liver injury (Lucendo-Villarin et al., 2020a; Szkolnicka et al., 2014), genetically modified to study gene function (Wang et al., 2019), and moved into 3D culture for longer-term experimentation (Lucendo-Villarin et al., 2020b). These approaches will be valuable to further determine which genes link metabolic disruption and steatosis and for high-throughput drug screening to identify targets for preclinical analysis.

In conclusion, we propose that steatotic HLCs represent a new and attractive tool to develop a deeper understanding of steatosis-associated biology and for the development of new therapeutics.

Limitations of the study

One limitation of this study is the use of AICAR to block PNC activity and limit fumarate accumulation (Chouchani et al., 2014). AICAR is also an AMP-activated protein kinase (AMPK) agonist (Zhao and Saltiel, 2020). AMPK is a regulator of cellular energy homeostasis, and its activation by Metformin, a commonly used treatment for type 2 diabetes, inhibits gluconeogenesis in the liver (Zhou et al., 2001), which may explain why we did not observe increased activity in this pathway. AICAR may have a number of additional effects, notably through downstream pathways, which make the interpretation of its effects problematic, and further studies exploring the effects of overexpression and/or silencing of metabolic enzymes using siRNA on lipid accumulation and the metabolome will be useful to delineate the precise pathways involved. Similarly, there is some evidence that AOA may exert effects upstream of the MAS, leading to inhibition of gluconeogenesis (Subramanian et al., 2007), supporting the need for additional experiments to dissect the precise effect of this inhibitor in the model presented here. Octanoic acid increases oxidative stress through ROS production (Scaini et al., 2012), so future studies should additionally measure oxidative stress and ROS levels in steatotic HLCs. Further studies are required to determine if the mitochondrial dysfunction is due to defects in individual respiratory complexes or changes in a combination of complexes and whether other aspects of mitochondrial respiration may become compromised with longer LPO exposure. Finally, LPO may induce ER stress (Lockman et al., 2016), which may influence mitochondrial oxygen consumption and contribute to the development of NAFLD (Liu and Green, 2019; Wang et al., 2011).

Resource availability

Lead contact

David C Hay: Center for Regenerative Medicine, University of Edinburgh, Institute for Regeneration and Repair, Edinburgh BioQuarter, 5 Little France Crescent, Edinburgh, EH16 4UH. davehay@talktalk.net.
Materials availability
This study did not generate new unique reagents.

Data and code availability
The accession number for transcriptomic sequencing data reported in this paper is GEO: GSE138052. The accession number for 5hmC sequencing data reported in this paper is GEO: GSE144955. Original raw GC-MS data have been deposited to Mendeley Data: https://data.mendeley.com/datasets/gd5k5psvf4/1; https://doi.org/10.17632/gd5k5psvf4.1.

Methods
All methods can be found in the accompanying Transparent methods supplemental file.

Supplemental information
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2020.101931.

Acknowledgments
MCS was supported by a British Heart Foundation PhD studentship (FS/16/54/32730) and the British Heart Foundation Centre of Research Excellence. SW-Z was funded by the Deutsche Forschungsgemeinschaft (SFB960). This work was supported in part by the Wellcome Trust [grant number 208400/Z/17/Z], and we thank HWB-NMR at the University of Birmingham for providing open access to their Wellcome Trust-funded NMR equipment. RNC and NMM were supported by a Wellcome Trust New Investigator Award to NMM (100981/Z/13/Z). MJL was supported by a Wellcome Trust PhD Fellowship as part of the Edinburgh Clinical Academic Track scheme (102839/Z/13/Z). RRM is supported by the Medical Research Council and by grants from the BBFRC. Research in RRM’s lab leading to these results is partly funded by the Innovative Medicine Initiative Joint Undertaking (IMI JU) under grant agreement number 115001 (MARCAR project: URL: http://www.imi-marcar.eu/). DCH, JMR, and BLV were supported with awards from the MRC Doctoral Training Partnership (MR/K01293/1) and the Chief Scientist Office (TCS/16/37). AJD was funded by the British Heart Foundation Centre of Research Excellence, University of Edinburgh. Our thanks go to the Wellcome Trust Clinical Research Facility Genetics Core, Western General Hospital, Edinburgh, UK. We thank Will Cawthorn for discussions about mitochondrial quantification. Graphical abstract and Figure 1A were created using the BioRender platform.

Author contributions
MCS was involved in conceptualization, methodology, validation, formal analysis, investigation, data curation, writing (original draft preparation, reviewing, and editing) and visualization. BLV, JMR, MJL, PDW, and AT were involved in methodology, validation, formal analysis, investigation, and writing (reviewing and editing). SW-Z and JPT were involved in software, formal analyses, data curation, and writing (reviewing and editing). RRM, CL, and DAT were involved in conceptualization, methodology, validation, formal analysis, investigation, data curation, provision of resources, writing (reviewing and editing), project administration, funding acquisition, and supervision. DCH and AJD were involved in conceptualization, methodology, validation, formal analysis, provision of resources, writing (reviewing and editing), project administration, funding acquisition, and supervision.

Declaration of interests
Professor David Hay is a founder, shareholder, and director in Stemnovate Limited. All other authors declare that they have no competing interests.

Received: August 20, 2020
Revised: November 20, 2020
Accepted: December 8, 2020
Published: January 22, 2021
References

Ajala Alexo, M.A., Rangel, V.L., Ristiguel, J.K., de Piedra, R.A., and Nonato, M.C. (2019). Structural, biochemical and biophysical characterization of recombinant human furamate hydratase. FEBS J. 286, 1925–1940.

Anstee, Q.M., and Goldin, R.D. (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1–16.

Asahi, M., and Jornayvaz, F.R. (2015). Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link? Mol. Cell. Endocrinol. 418, 55–65.

Atanassovska, B., Rensen, S.S., van der Sijde, M.R., Mol, M., Kuiper, V., Jonkers, I., Wijhoff, S., Shiri-Sverdlov, R., Greve, J.W.F., Faber, K.N., et al. (2017). A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis. Hepatology 66, 794–808.

Bhargava, P., Fitzgerald, K.C., Venkata, S.L.V., Bhargava, P., Fitzgerald, K.C., Venkata, S.L.V., and Beard, D.A. (2009). Effect of dietary monosodium glutamate and dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. Ann. Clin. Transl. Neurol. 6, 33–45.

Boutagy, N.E., Pyne, E., Rogers, G.W., Ali, M., Huver, M.W., and Frisard, M.I. (2015). Isolation of mitochondria from minimal quantities of mouse skeletal muscle for high throughput microplate respiratory measurements. J. Vis. Exp. 2015, 53217.

Cazanave, S., Podtelezhnikov, A., Jensen, K., Seneshaw, M., Komberg, M.D., Mowry, E.M., Haughey, N.J., and Calabresi, P.A. (2019). Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. Ann. Clin. Transl. Neurol. 6, 33–45.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Banda, L., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Chen, M.L., Shen, F., Huang, W., Qi, J.H., Wang, Y., Feng, Y.Q., Liu, S.M., and Yuan, B.F. (2013). Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydroxymethylcytosine in human liver function. Clin. Chem. 59, 824–832.

Chouchani, E.T., Pell, V.R., Gaude, E., Aksentijevich, I., Sundier, S.Y., Robb, E.L., Logan, J., and Hay, D. (2020b). Measurement of mitochondrial and cytosolic free radicals in living cells by capillary electrophoresis-quadrupole TOF mass spectrometry. Clin. Chem. 66, 101931, January 22, 2021.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.

Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Mifsud, C., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193.
Lyall, M.J., Thomson, J.P., Cartier, J., Ottaviano, R., Kendall, T.J., Meehan, R.R., and Drake, A.J. (2020). Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. Epigenetics 15, 61–71.

Lynn, R., and Guynn, R.W. (1978). Equilibrium constants under physiological conditions for the reactions of succinyl coenzyme A synthetase and the hydrolysis of succinyl coenzyme A to coenzyme A and succinate. J. Biol. Chem. 253, 2546–2553.

Nikolaou, N., Gathercole, L.L., Marchand, L., Althari, S., Dempster, N.J., Green, C.J., van de Bunt, M., McNeil, C., Arvaniti, A., Hughes, B.A., et al. (2019). AKR1D1 is a novel regulator of the hydrolysis of succinyl coenzyme A to coenzyme A and succinate. J. Biol. Chem. 253, 2546–2553.

Oligschlaeger, Y., and Shiri-Sverdlov, R. (2020). NAFLD preclinical models: more than a handful, less of a concern? Biomedicines 8, 28.

Parafati, M., Kirby, R.J., Khorasanizadeh, S., Rastinejad, F., and Malany, S. (2018). A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. BMC Genomics 17, 462.

Satapati, S., Sunny, N.E., Kecejoza, B., Fu, X., He, T.T., Méndez-Lucas, A., Shelton, J.M., Perales, J.C., Browning, J.D., and Burgess, S.C. (2012). Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J. Lipid Res. 53, 1080–1092.

Satapati, S., Kecejoza, B., Duarte, J.A.G., Fletcher, J.A., Reynolds, L., Sunny, N.E., He, T., Arya Nair, L., Livingston, K., Fu, X., et al. (2015). Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J. Clin. Invest. 125, 4447–4462.

Scaini, G., Simon, K.R., Tonin, A.M., Busanello, E.N.B., Mora, A.P., Ferreira, G.C., Wajner, M., Streck, E.L., and Schuck, P.F. (2012). Toxicity of octanoate and decanoate in rat peripheral tissues: evidence of bioenergetic dysfunction and oxidative damage induction in liver and skeletal muscle. Mol. Cell. Biochem. 361, 329–335.

Schöth, H.B., Boström, A., Murphy, S.K., Erhart, W., Hampe, J., Moylan, C., and Mwinyi, J. (2016). A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. BMC Genomics 17, 462.

Short, K.R., Bigelow, M.L., Kahl, J., Singh, R., Coenens-Schimke, J., Raghavakaimal, S., and Nair, K.S. (2005). Decline in skeletal muscle mitochondrial function with aging in humans. Proc. Natl Acad. Sci. U. S. A. 102, 5618–5623.

Subramanian, R.K., Kasumov, T., Yang, L., Cendrowski, A., David, F., Minkler, P.E., Hoppel, C.L., Anderson, V.A., and Brunengraber, H. (2007). Reassessment of the Mechanisms by Which Aminooxyacetate (AOA) Inhibits Glucuronogenesis (GNG) from Lactate (John Wiley & Sons, Ltd).
Supplemental Information

A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis

Matthew C. Sinton, Jose Meseguer-Ripolles, Baltasar Lucendo-Villarin, Sara Wernig-Zorc, John P. Thomson, Roderick N. Carter, Marcus J. Lyall, Paul D. Walker, Alpesh Thakker, Richard R. Meehan, Gareth G. Lavery, Nicholas M. Morton, Christian Ludwig, Daniel A. Tennant, David C. Hay, and Amanda J. Drake
Figure S1. Validation of mRNA sequencing analysis by RT-qPCR. Data were analysed using two-tailed Student t-test and expressed as mean ± SD, *p<0.05, ****p<0.0001. Related to Figure 2.

Figure S2. Representative blot of succinate dehydrogenase subunit A (SDHA) and pyruvate dehydrogenase (PDH) α1 and α2 subunits, with total protein staining. Molecular weight band of SDHA = 70 kDa. Molecular weight band of PDh = 38 kDa. Related to Figure 3.
**Figure S3.** Measurement of mitochondrial (mitochondrial region 2 (MT2); mitochondrial region 3 (MT3)) and nuclear (beta-globin (HBB)) DNA. Data are expressed as mean ± SD. Related to Figure 3.

**Figure S4.** Steatotic HLCs show a moderate negative correlation between promoter 5hmC enrichment and mRNA expression, Related to Figure 7.
| Gene  | Forward sequence        | Reverse sequence         | Probe |
|-------|-------------------------|--------------------------|-------|
| TBP   | GAACATCATGGATCAGAACA    | ATAGGGATTCCGGGAGTCAT     | 87    |
| NANO   | ATGCCTACACGGGACTGT      | CAGGGCTGTCTGGAATAAGC     | 69    |
| ALB   | GTGAGGTTGCTCATCGGTTT    | GAGCAGGGCAATCAACACC      | 7     |
| HNF4A | AGCAACGGCAAGATGTGTGA    | TCAGACCCTGAGCCACCAT     | 27    |
| PLIN2 | TCAGCTCCATTCTACTGTCACC  | CCTGAATTTCCTGGATTGCACT   | 72    |
| PLIN4 | AGTCCAAGGCGGACAC       | TGCTGGGCTTTTCAATC       | 1     |
| PLIN5 | TACAGTGAGGCGAGAGACAG   | CGCACAGCGGTTTCAG        | 3     |
| PCK2  | CGAAAGCTCCCCAAGTACAA   | GCTCTCTACTCGTGCCACATC   | 20    |
| G6PD  | AACAGAGTGAGCCTTTTCA    | GGAGGCTGATCATCGTACT     | 5     |
| PLIN2 | TCAGCTCCATTCTACTGTCACC | CCTGAATTTCCTGATTGCACT   | 72    |
| HK1   | GACCAAGTTTCTCTTCAGATCG | CCTAGCTGCTGGAGGATAGC    | 1     |
| HIF1A | GATAGCAAGACTTTCTCAGTCG | TGGCTCATATGCCATCAATTC   | 64    |

Table S1. Primer pairs and probes used to quantify mRNA expression, Related to Figure 1 and Figure 2.

| Gene | Forward Primer | Reverse Primer |
|------|----------------|----------------|
| MT1  | CTCACTCTCAGTGCCAAGAA | TGAGAATGAGTGAGGCAGT |
| MT2  | ACCCAACCATACATGCCATA | GTGTGACATGCACGCCATC |
| HBB  | TGGTGCATCTGACTCCTGAG | TCTCCACATGGGCAAGTTC |

Table S2. Primer pairs used to quantify mitochondrial and nuclear DNA, Related to Figure 3.
Table S3. Primer sequences for validation of DNA immunoprecipitation protocol, Related to Figure 7.

| Gene                      | Forward sequence | Reverse sequence |
|---------------------------|------------------|------------------|
| GAPDH promoter – negative control | CGGCTACTAGCGGTTTTACG | AAGAAGATGCGGCTGACTGT |
| H19 genic – positive control | GATCTCGGCCCTAGTGAA | GTGATGTGTGAGCCTGACT |
| UBIAD1 genic – positive control | CTCTTCCTCCTCCTCGTCCT | CATCCAGGAACCACAGTCCT |
| Pathway                                                | Benjamini | Genes                                                                                       |
|--------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------|
| hsa04713: Circadian entrainment                         | 4.20      | ADCY4, ADCY2, CACNA1I, GRIN1, GRI3A, PRK1G1, PRKCB, KCNJ5, P2RX5, GRIN2D, CACNA1G, RYR1, GNG2, PER3, GNG4, MTNR1A |
| hsa04724: Glutamatergic synapse                         | 4.15      | ADCY4, DLGAP1, ADCY2, GRIK2, GRIN1, GRIK5, GRIN3B, GRI3A, SHANK1, PRKCB, SLC17A7, GLS2, GRM4, PLCB4, GRIN2D, PLA2G4F, GNG2, GNG4, PLA2G4D |
| hsa04725: Cholinergic synapse                           | 3.59      | ADCY4, ACHE, ADCY2, KCNJ12, KCNJ14, PRKCB, KCNJ4, KCNO4, KCNQ3, CHRM4, PLCB4, GNG2, PIK3R5, GNG4, KCNQ1, CHRNA3 |
| hsa04750: Inflammatory mediator regulation of TRP channels | 3.31      | ADCY4, ADCY2, TRPM8, TRPV2, ASIC3, ASIC1, PRKCB, PLCB4, PLA2G4F, PIK3R5, ALOX12, NGF, PLA2G4D |
| hsa05414: Dilated cardiomyopathy                        | 3.26      | ADCY4, ADCY2, ADRB1, SGCG, CACNG8, ITGA8, ITGA7, CACNB1, CACNB4, TNNI3, ITGA2B               |
| hsa04911: Insulin secretion                             | 3.23      | TRPM4, ADCY4, ADCY2, PLCB4, KCNN1, KCN3, ATP1A3, RIMS2, PCLO, KCNJ11, PRKCB                  |
| hsa04726: Serotonergic synapse                          | 3.14      | GABBR2, PRKCB, KCNJ5, PLCB4, ALOX15B, HTR7, SLC18A2, PLA2G4F, GNG2, HTR1D, HTR3A, GNG4, ALOX12, PLA2G4D |
| hsa04514: Cell adhesion molecules (CAMs)                | 2.81      | ICAM1, NTNG1, NTNG2, CLDN10, CD40, HLA-DMB, CDH4, HLA-G, NCAM2, ITGA8, NLGN4X, PECAM1, CNTN1, HLA-DOA, CD6, ICOSLG |
| hsa04921: Oxytocin signalling pathway                   | 2.66      | ADCY4, ADCY2, CACNG8, CACNB1, CACNB4, KCNJ12, TRPM2, KCNJ14, PRKCB, KCNJ5, KCNJ4, PLCB4, RYR1, PLA2G4F, NFATC1, PLA2G4D |
| hsa04080: Neuroactive ligand-receptor interaction       | 2.43      | F2RL2, C5AR1, GABRB2, GRIK2, GRIN1, GABBR1, GRIK5, LPAR3, GRI3A, GRIN3B, P2RX5, GRM4, SSTR2, ADRB1, S1PR1, CHRM4, CHRNA9, SSTR1, GRIN2D, HTR7, CHRNA5, ADRA1A, CALCRL, HTR1D, CHRNA3, GRID1, MTNR1A |
| hsa04024: cAMP signalling pathway                       | 2.39      | ADCY4, HCN2, ADCY2, GRIN1, GABBR1, ATP1A3, GRIN3B, GRIA3, TNNI3, GLU1, SSTR2, ADRB1, SSTR1, PDE4A, GRIN2D, PIK3R5, HTR1D, HCAR2, NFATC1 |
| hsa04020: Calcium signalling pathway                    | 2.37      | SLC8A3, ADCY4, SLC8A2, ADCY2, CACNA1I, GRIN1, PRKCB, P2RX5, PLCB4, ADRB1, ATP2A3, GRIN2D, HTR7, CACNA1G, RYR1, ADRA1A, PLCD1 |
| hsa04014: Ras signalling pathway                        | 2.32      | FGF19, FGF5, FLT4, FGF17, EFNA3, GRIN1, FGF11, PRKCB, RASAL1, HTR7, RASGRP2, PLA2G4F, PLA1A, GNG2, PIK3R5, NGFR, SYNGAP1, GNG4, RASA4, PLA2G4D, NGF |

| Pathways with downregulated genes                       | Benjamini | Genes                                                                                       |
|--------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------|
| hsa05322: Systemic lupus erythematosus                  | 6.65      | HIST1H2AB, C7, HIST1H4L, HIST1H2AG, C6, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BM, HIST1H4A, HIST1H2BL, HIST1H2B1, HIST2H2AC, HIST1H2BJ, H2AFX, HIST3H2BB, HIST1H4I, HIST1H4J, HIST2H3A, HIST1H3J, HIST1H2BB, HIST1H2BC, |
| KEGG Pathway                        | Score | Genes                                                                 |
|------------------------------------|-------|----------------------------------------------------------------------|
| hsa00140: Steroid hormone biosynthesis | 6.43  | HSD3B2, CYP3A4, CYP3A5, CYP3A7, HSD3B1, CYP11A1, HSD17B1, UGT1A9, CYP7A1, UGT2B11, UGT2B4, HSD17B6, UGT2B10, UGT2A3, SULT1E1, UGT2B15, AKR1D1, CYP19A1 |
| hsa00053: Ascorbate and aldarate metabolism | 5.37  | UGTA9, UGT2B11, RGN, UGT2B4, UGT2B10, UGT2A3, UGT2B15               |
| hsa04610: Complement and coagulation cascades | 5.10  | KNG1, F11, PLAT, MBL2, C7, MASP2, F13A1, C6, F9, C4BPB, C4BPA, F13B, F3, KLKB1, SERPINA5, SERPIND1, CPB2 |
| hsa00040: Pentose and glucuronate interconversions | 5.02  | UGTA9, KL, AKR1B10, UGT2B11, UGT2B4, UGT2B10, UGT2A3, UGT2B15       |
| hsa05034: Alcoholism                | 4.92  | HIST1H2AB, HIST1H4L, HIST1H2AG, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BM, HIST1H4A, HIST1H2BL, HIST1H2BI, HIST2H2AC, HIST1H2BJ, H2AFX, HIST3H2BB, HIST1H4I, HIST1H4J, HIST2H3A, HIST1H3J, HIST1H2BB, HIST1H2BC, HIST1H2BE, HIST1H2BF, HIST1H2BG, HIST1H2BH, FO5B, HIST2H3C, HIST2H3D, HIST2H2BF, NTRK2, HIST1H3A, HIST1H3B, HIST1H2AI, HIST1H2AH, HIST1H3C, HIST1H3E, HIST1H2AJ, HIST1H3F, HIST1H2AM, HIST1H3G, HIST1H2AL, HIST1H3H, HIST1H3I |
| hsa00982: Drug metabolism - cytochrome P450 | 4.88  | GSTA1, CYP3A4, GSTA2, CYP3A5, ALDH3B2, ADH1B, ADH1A, FMO5, UGT1A9, FMO1, ADH4, UGT2B11, UGT2B4, UGT2A3, UGT2B10, UGT2B15 |
| hsa00830: Retinol metabolism        | 4.86  | CYP3A4, CYP3A5, UGT1A9, CYP3A7, ADH4, UGT2B11, ADH1B, UGT2B4, CYP26A1, HSD17B6, ADH1A, UGT2B10, UGT2A3, UGT2B15, RDH5 |
| hsa05204: Chemical carcinogenesis   | 4.40  | GSTA1, CYP3A4, GSTA2, CYP3A5, CYP3A7, NAT2, ADH1B, ALDH3B2, ADH1A, CYP3A43, UGT1A9, ADH4, UGT2B11, UGT2B4, UGT2A3, UGT2B10, UGT2B15 |
| hsa00983: Drug metabolism - other enzymes | 4.05  | CYP3A4, UGT1A9, NAT2, UGT2B11, UGT2B4, UGT2B10, UGT2A3, UGT2B15, TK1 |
| hsa00980: Metabolism of xenobiotics by cytochrome P450 | 3.92  | GSTA1, CYP3A4, CYP3A5, GSTA2, ALDH3B2, ADH1B, ADH1A, UGT1A9, ADH4, UGT2B11, UGT2B4, UGT2A3, UGT2B10, UGT2B15 |
| hsa04110: Cell cycle               | 3.01  | CDC6, CDK1, PKMYT1, TTK, CDC20, ESP1, PTTG1, MCM2, CDC25C, CCNB1, CDKN1C, MAD2L1, CCNB2, PLK1, CDKN2C, BUB1, BUB1B, CCNA2 |
| hsa04114: Oocyte meiosis           | 2.61  | CCNB1, CDK1, MAD2L1, CCNB2, PLK1, SG01, BUB1, FBXO43, PKMYT1, AURKA, ESP1, CDC20, PTTG1, CDC25C |
| hsa05202: Transcriptional misregulation in cancer | 2.36  | PLAT, HIST2H3A, NFKBIZ, HIST1H3J, MMP9, MMP3, HIST2H3C, HIST2H3D, HHEX, EYA1, CDKN2C, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3I |
Table S4. Upregulated and downregulated KEGG pathways, Related to Figure 2.
| Ensembl ID     | Gene   | Log$_2$FC | padj     |
|---------------|--------|-----------|----------|
| ENSG00000197444 | OGDHL  | 1.08547769 | 3.29E-30 |
| ENSG00000166411 | IDH3A  | 0.74709247  | 7.70E-20 |
| ENSG00000204370 | SDHD   | 0.3777972   | 0.0003   |
| ENSG00000100412 | ACO2   | 0.26021698  | 0.002    |
| ENSG00000146701 | MDH2   | 0.23945724  | 0.0009   |
| ENSG00000073578 | SDHA   | -0.1593416  | 0.03     |
| ENSG00000138413 | IDH1   | -0.1812103  | 0.03     |
| ENSG00000168291 | PDHB   | -0.2026402  | 0.02     |
| ENSG00000131828 | PDHA1  | -0.2107741  | 0.01     |
| ENSG00000163541 | SUCLG1 | -0.2111892  | 0.006    |
| ENSG00000143252 | SDHC   | -0.2414483  | 0.02     |
| ENSG00000150768 | DLAT   | -0.2619025  | 0.0003   |
| ENSG00000091483 | FH     | -0.4936542  | 1.01E-12 |
| ENSG00000014641 | MDH1   | -0.5085681  | 3.36E-13 |
| ENSG00000101365 | IDH3B  | -0.5405112  | 5.07E-13 |
| ENSG00000067829 | IDH3G  | -0.5829934  | 1.14E-09 |
| ENSG00000100889 | PCK2   | -0.5852916  | 3.07E-18 |
| ENSG00000131473 | ACLY   | -0.6074454  | 9.80E-24 |
| ENSG00000173599 | PC     | -0.9409933  | 3.13E-37 |
| ENSG00000182054 | IDH2   | -1.0677314  | 8.52E-45 |

Table S5. [Dysregulated genes in the TCA Cycle KEGG pathway], Related to Figure 2.
| **Ensembl ID**     | **Gene**     | **Log_{2}FC** | **padj** |
|-------------------|-------------|---------------|----------|
| ENSG00000147614   | ATP6V0D2    | 3.973933876   | 9.35E-140|
| ENSG00000198763   | ND2         | 1.473526224   | 2.53E-06 |
| ENSG00000198888   | ND1         | 1.363322749   | 6.19E-05 |
| ENSG00000198840   | ND3         | 1.217622162   | 2.54E-33 |
| ENSG00000212907   | ND4L        | 1.095495883   | 0.0001   |
| ENSG00000198886   | ND4         | 0.866690501   | 0.002    |
| ENSG000001114573  | ATP6V1A     | 0.803262336   | 2.80E-32 |
| ENSG00000198804   | COX1        | 0.656245362   | 1.17E-09 |
| ENSG00000198899   | ATP6        | 0.634543196   | 0.009    |
| ENSG00000198938   | COX3        | 0.632275024   | 2.80E-10 |
| ENSG00000171130   | ATP6V0E2    | 0.589272395   | 2.52E-11 |
| ENSG00000198727   | CYTB        | 0.557687429   | 0.02     |
| ENSG00000047249   | ATP6V1H     | 0.506014583   | 5.94E-13 |
| ENSG000001117410  | ATP6V0B     | 0.479535962   | 2.58E-11 |
| ENSG00000147416   | ATP6V1B2    | 0.437789019   | 5.51E-09 |
| ENSG00000128609   | NDUFA5      | 0.381648881   | 0.0008   |
| ENSG00000204370   | SDHD        | 0.377797199   | 0.0003   |
| ENSG00000198712   | COX2        | 0.322901415   | 0.005    |
| ENSG00000073678   | SDHA        | -0.159341647  | 0.04     |
| ENSG00000023228   | NDUF51      | -0.210017339  | 0.002    |
| ENSG00000112695   | COX7A2      | -0.211631763  | 0.02     |
| ENSG00000156467   | UQCRB       | -0.2162753    | 0.03     |
| ENSG00000167792   | NDUFV1      | -0.222597617  | 0.007    |
| ENSG00000135390   | ATP5MC2     | -0.22831627   | 0.002    |
| ENSG00000143252   | SDHC        | -0.24144827   | 0.02     |
| ENSG00000160194   | NDUFV3      | -0.242343108  | 0.004    |
| ENSG00000131100   | ATP6V1E1    | -0.274149444  | 2.61E-05 |
| ENSG00000189043   | NDUFA4      | -0.277227615  | 0.0001   |
| ENSG00000176340   | COX8A       | -0.278696825  | 0.001    |
| ENSG00000165264   | NDUF6B      | -0.28300413   | 0.005    |
| ENSG00000213619   | NDUF3       | -0.29075047   | 0.001    |
| ENSG00000178741   | COX5A       | -0.297956503  | 9.27E-05 |
| ENSG00000110719   | TCIRG1      | -0.300385483  | 0.002    |
| ENSG00000090266   | NDUFB2      | -0.301527793  | 0.001    |
| ENSG00000174886   | NDUFA11     | -0.318594422  | 0.001    |
| ENSG00000169021   | UQCRFS1     | -0.319382279  | 2.33E-05 |
| ENSG00000130414   | NDUFA10     | -0.320916351  | 3.89E-05 |
| ENSG00000131143   | COX4I1      | -0.336149045  | 2.75E-07 |
| ENSG00000158864   | NDUF2S      | -0.343567449  | 4.23E-06 |
| ENSG00000139180   | NDUFA9      | -0.357605693  | 0.0006   |
| ENSG000000047799  | NDUFAB1     | -0.360587197  | 2.52E-05 |
| ENSG00000184076   | UQCR10      | -0.375287362  | 3.00E-06 |
| ENSG00000116459   | ATP5PB      | -0.379803823  | 9.50E-08 |
| ENSG00000126267   | COX6B1      | -0.388197692  | 3.84E-08 |
| ENSG00000100554   | ATP6V1D     | -0.405728961  | 7.75E-08 |
| ENSG00000131495   | NDUFA2      | -0.419069805  | 1.65E-06 |
| ENSG00000115286   | NDUF7       | -0.422028053  | 0.0002   |
| ENSG00000136888   | ATP6V1G1    | -0.428892928  | 2.02E-09 |
| ENSG00000183648   | NDUFB1      | -0.432392964  | 0.0003   |
| ENSG00000154518   | ATP5MC3     | -0.445435152  | 1.00E-08 |
| ENSG00000125356   | NDUFA1      | -0.459056555  | 2.84E-07 |
| ENSG00000179091   | CYC1        | -0.468189203  | 1.54E-09 |
| Gene Symbol | Gene Name | Log2 Ratio | Adj P-value |
|-------------|-----------|------------|-------------|
| ENSG00000127540 | UQCR11 | -0.475454692 | 4.04E-09 |
| ENSG00000110955 | ATP5F1B | -0.49393262 | 1.83E-16 |
| ENSG00000099795 | NDUFB7 | -0.509075592 | 1.10E-09 |
| ENSG00000168653 | NDUFS5 | -0.520875625 | 8.23E-11 |
| ENSG00000159720 | ATP6V0D1 | -0.540902137 | 6.67E-12 |
| ENSG00000147123 | NDUFB11 | -0.542107011 | 1.51E-08 |
| ENSG00000178127 | NDUFV2 | -0.542969651 | 0.006 |
| ENSG00000124172 | ATP5F1E | -0.574462256 | 1.96E-13 |
| ENSG00000152234 | ATP5F1A | -0.606022757 | 1.10E-17 |
| ENSG00000140990 | NDUFB10 | -0.613088113 | 6.15E-12 |
| ENSG00000119013 | NDUFB3 | -0.65837698 | 2.66E-11 |
| ENSG00000169020 | ATP5ME | -0.663226048 | 5.18E-18 |
| ENSG00000159199 | ATP5MC1 | -0.712677613 | 1.05E-19 |
| ENSG00000241468 | ATP5MF | -0.735984185 | 1.21E-15 |
| ENSG00000099624 | ATP5F1D | -0.737422752 | 3.56E-17 |
| ENSG00000169429 | CXCL8 | -0.820462236 | 3.09E-17 |
| ENSG00000164405 | UQCRQ | -0.860634282 | 1.66E-38 |
| ENSG00000198695 | ND6 | -0.979723775 | 1.42E-08 |
| ENSG00000143882 | ATP6V1C2 | -1.543440061 | 0.005 |

Table S6. [Dysregulated genes in the Oxidative Phosphorylation KEGG pathway], Related to Figure 2
| Ensembl ID       | Gene symbol | mRNA expression fold change | 5hmC fold change |
|------------------|-------------|-----------------------------|------------------|
| ENSG000000181418 | DDN         | 3.57                        | -2.84            |
| ENSG000000105131 | EPHX3       | 2.38                        | -3.82            |
| ENSG000000086619 | ERO1B       | 1.65                        | 4.05             |
| ENSG00000147408 | CSGALNACT1  | 1.33                        | 3.09             |
| ENSG00000149927 | DOC2A       | 1.26                        | -2.49            |
| ENSG00000142156 | COL6A1      | 1.24                        | 3.13             |
| ENSG00000137752 | CASP1       | 0.98                        | 2.44             |
| ENSG00000119900 | OGFRL1      | 0.71                        | 2.21             |
| ENSG00000145247 | OCIAD2      | 0.71                        | 3.02             |
| ENSG00000183044 | ABAT        | -1.26                       | 3.04             |
| ENSG00000144395 | CCDC150     | -1.50                       | 3.36             |
| ENSG00000167874 | TMEM88      | -2.02                       | 3.60             |

**Table S7.** [Promoter regions of genes with both altered mRNA expression and enrichment of 5hmC], Related to Figure 7.
Differentiation of pluripotent human stem cells to hepatocyte-like cells and induction of intracellular lipid accumulation

Human female H9 pluripotent stem cells (PSCs) were differentiated to hepatocyte-like cells (HLCs) as previously described (Wang et al., 2017). Unless otherwise stated, compounds for this protocol were purchased from Thermo Fisher. Briefly, H9 cells were cultured on Laminin 521 coated plates, with mTeSR1 media, which contained 10 μM ROCK inhibitor. H9s were initially differentiated to an endoderm phenotype in RPMI 1640 media containing 100 ng/mL Activin A (R & D Systems), and 50 ng/mL Wnt3A (Peprotech). Endodermal cells were then differentiated to a hepatoblast phenotype by culturing in Knockout DMEM, containing 20% Knockout Serum Replacement. Finally, cells were differentiated to a HLC phenotype by culturing in HepatoZYME media containing 10 ng/mL hepatocyte growth factor (Peprotech), 20 ng/mL oncostatin M (Peprotech), and 10 μM hydrocortisone 21-hemisuccinate (Sigma Aldrich), until day 17, at which point the cells were used for the assays described in this manuscript.

HLCs were cultured in a 96-well format for measurements of lipid accumulation and in a 6-well format for all other analyses. Each well is a separate differentiation event and represents a biological replicate. Intracellular lipid accumulation was induced in HLCs, as previously described (Lyall et al., 2018). Briefly, at day 17, HLCs were incubated in HepatoZYME media only (controls) or HepatoZYME media containing a cocktail of sodium l-lactate (L; 10mM), sodium pyruvate (P; 1 mM) and octanoic acid (O; 2 mM) (Sigma, Gillingham, UK) (LPO) for a period of 48 hours. For isotopic tracing studies, lactate was replaced with 13C3-lactate (CK Isotopes, CLM-1579-05). For mechanistic studies, HLCs were exposed to either 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5'-monophosphate (AICAR; 1mM; Sigma-Aldrich, A1393-50MG), O-(Carboxymethyl)hydroxylamine hemihydrochloride (AOA; 100 μM ; Sigma-Aldrich, C13408-1G) or AICAR combined with monomethyl fumarate (50 μM; Sigma-Aldrich, 651419-1G) for the same duration as LPO.
Cell mitochondrial stress test assay
The oxygen consumption rate (OCR) of LPO-exposed HLCs was measured using the Agilent Seahorse XF Cell Mito Stress Test Kit (Agilent, 103015-100) on a Seahorse XF Analyser (Agilent, California, USA). Data were collected from two separate plates, with each well representing a biological replicate and each plate representing a technical replicate. Analyses were performed under basal conditions and following treatment with oligomycin A (an ATPase inhibitor), carbonyl-cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP; an ETC uncoupler), and combined rotenone and antimycin A (inhibitors of complex I and III, respectively). Two concentrations of FCCP (0.5 μM and 1.0 μM) were used for optimisation. Since replicates within each group responded similarly to each other, results were combined. OCR was normalised to total protein for each well, using the sulforhodamine B (SRB) assay, as previously described (Orellana and Kasinski, 2016), but with spectrophotometric measurements read at 540 nm.

Citrate synthase assay
Citrate synthase activity was assessed as a readout of mitochondrial integrity (Boutagy et al., 2015; Short et al., 2005). Mitochondria were isolated using the Mitochondria Isolation Kit for Cultured Cells (Thermo Scientific, 89874), as per the manufacturer’s instructions, selecting option A for isolation. Citrate synthase activity, a marker of mitochondrial integrity, was then measured using the Citrate Synthase Activity Colorimetric Assay Kit (BioVision, K318), as per the manufacturer’s instructions.

Protein Extraction
Adherent HLCs were washed once with ice-cold PBS, before incubating in ice-cold RIPA Lysis and Extraction Buffer (Thermo Scientific, 89900) supplemented with cOmplete Protease
Inhibitor Cocktail tablets (1/10 mL buffer; Roche, 11697498001). The suspended HLCs were placed on ice for 30 minutes, vortexing every 3 minutes, before centrifuging for 20 min at 4°C, 12,000 rpm. The supernatant was collected and stored at -80 °C until needed.

**Western blot analysis**

Protein quantification was performed using the Qubit Protein Assay Kit (Invitrogen, Q33211), as per the manufacturer’s instructions. Protein concentration was measured using a Qubit Fluorometer (Invitrogen, Massachusetts, USA). Equal concentrations (50 μg) of HLC protein extract in 4 x Sample Loading Buffer (Li-Cor, 928-40004) were loaded onto NuPAGE 4-12% Bis-Tris Protein Gels (Invitrogen, NP0326BOX). Following resolution, protein was transferred to a methanol-activated polyvinylidene difluoride (PVDF) membrane. Protein transfer was measured using Revert 700 Total Protein Stain Kit (Li-Cor, 926-11010) as per the manufacturer’s instructions. To enable probing with different antibodies, membranes were then sliced (images shown in Figure S1), blocked with Tris-buffered saline containing Tween 20 (TBST) and 5% skimmed milk powder, and incubated with either Pyruvate Dehydrogenase (staining total α1 and α2 subunits) (C54G1) Rabbit mAb (Cell Signaling Technology, 3205) or SDHA (D6J9M) XP Rabbit mAb (Cell Signaling Technology, 11998), both a 1:1000 dilution. The membranes were washed in TBST before incubating with the secondary antibody, IRDye 680RD Donkey anti-Mouse IgG (Li-Cor, 926-68072) at a 1:10,000 dilution, for 1 h at room temperature, in the dark, with shaking. Blots were visualised on a Li-Cor Odyssey CLx (Li-Cor, Nebraska, USA), and bands normalised to the Revert 700 Total Protein Stain, as per the manufacturer’s instructions.

**RNA-seq analysis**

Total RNA was extracted from HLCs using the Monarch® Total RNA Miniprep Kit (New England BioLabs, T2010). RNA integrity was assessed using a Bioanalyzer (Agilent) with the RNA 6000 Nano kit. All samples had a RIN value >7.0. mRNA sequencing was performed on 3 biological replicates per group by the Beijing Genomics Institute (BGI) (Shenzhen, China).
Library preparation was performed with the TruSeq Stranded mRNA Library Preparation kit (Illumina, RS-122-2101), with additional use of the Ribo-Zero Gold rRNA Removal Kit (Illumina, MRZG12324). Paired-end sequencing was performed on an Illumina HiSeq 4000, with each sample sequenced to a depth >60 million reads. The generated FASTQ files were trimmed to remove adapters, using Trimmomatic (version 0.36) (Bolger et al., 2014), before performing quality control with FastQC (version 0.11.4) (Andrews). Alignment was performed against the *Homo sapiens* GRCh19 assembly. The assembly was first indexed using STAR (version 2.5.1b) before mapping trimmed reads, using STAR (version 2.5.1b) in paired-end mode with default behaviour (Dobin and Gingeras, 2015). Duplicate reads were removed using Picard (version 2.7.11) (2018), before using featureCounts to generate raw read counts for each gene. Differential gene expression (DEG) analysis was performed using DESeq2 (Love et al., 2014). Heatmaps were generated with Heatmapper (Babicki et al., 2016).

Pathway enrichment analysis was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) function (Kanehisa, 2019; Kanehisa and Goto, 2000; Kanehisa et al., 2019) of the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Huang et al., 2009a, 2009b).

**Real-time quantitative PCR**

RNA was taken from that prepared for RNA-sequencing. cDNA was generated using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, 4368814). A master mix was prepared using PerfeCTa FastMix II (Quanta Biosciences, Inc., 95118-250). cDNA was amplified and quantified using the Universal Probe Library (Roche, Burgess Hill, UK) system on a Roche LightCycler 480 (Roche Diagnostics Ltd, Switzerland). Primer sequences and Universal Probe Library probes are detailed in Table S1.

For quantifying mitochondrial and nuclear DNA, we purified DNA using the Monarch® Genomic DNA Purification Kit (NEB, USA), as per the manufacturer’s instructions. DNA was quantified by using the Luna® Universal qPCR Master Mix (NEB, USA) on a Roche
NMR Spectroscopy

This protocol was previously described by Hollinshead et al (Hollinshead et al., 2018). At the conclusion of tracer experiments, cells were washed with 2 mL ice-cold 0.9% saline solution and quenched with 0.3 mL pre-chilled methanol (-20 °C). After adding an equal volume of ice-cold HPLC-grade water containing 1 µg/mL D6-glutaric acid (C/D/N Isotopes Inc), cells were collected with a cell scraper and transferred to tubes containing 0.3 mL of chloroform (-20 °C). The extracts were shaken at 1400 rpm for 20 min at 4 °C and centrifuged at 16,000 x g for 5 min at 4 °C. Then, 0.3 mL of the upper aqueous phase was collected and evaporated in eppendorfs, under a vacuum using a Savant™ SpeedVac™ Concentrator (ThermoFisher). These samples were used either for NMR spectroscopy of for GC-MS. For NMR, dried samples were re-suspended in 60 µL of 100 mM sodium phosphate buffer (pH 7.0) containing 500 µM DSS and 2 mM Imidazole, 10% D20, pH 7.0. Samples were vortexed, sonicated (5-15 min) and centrifuged briefly, before transferred to 1.7 mm NMR tubes using an automated Gilson. One-dimensional (1D)-^1^H NMR spectra and two-dimensional (2D)-^1^H,^1^3^C Heteronuclear Single Quantum Coherence Spectroscopy (HSQC) NMR spectra were acquired using a 600 MHz Bruker Avance III spectrometer (Bruker Biospin) with an inverse cryogenic probe for 1.7 mm NMR sample tubes, fitted with a z-axis pulsed field gradient, at 300 K. Spectral widths were set to 13 and 160 ppm for the ^1^H and ^1^3^C dimensions, respectively. For the indirect (^1^3^C) dimension of the 2D-^1^H,^1^3^C HSQC NMR spectra, 1228 out of 4096 (30%) data points were acquired using a non-uniform sampling scheme. ^1^3^C-^1^3^C splittings were enhanced 4-fold in the ^1^3^C dimension. Each sample was automatically tuned, matched and then shimmed (1D-TopShim) to a DSS line width of <1 Hz before acquisition of the first spectrum. Total experiment time was ~15 min per sample for 1D-^1^H NMR spectra and 1 h per sample for 2D-^1^H,^1^3^C HSQC NMR spectra. 1D-^1^H NMR spectra were processed using the
MATLAB-based MetaboLab software (Ludwig and Günther, 2011). All 1D data sets were apodized using a 0.3 Hz exponential window function and zero-filled to 131,072 data points before Fourier Transformation. The chemical shift was calibrated by referencing the DSS signal to 0 ppm. 1D-\(^1\)H NMR spectra were manually phase corrected. Baseline correction was achieved using a spline function (Ludwig and Günther, 2011). 1D-\(^1\)H-NMR spectra were exported into Bruker format for metabolite identification and concentration determination using Chenomx 7.0 (Chenomx INC). 2D-\(^1\)H,\(^{13}\)C HSQC NMR spectra were reconstructed using compressed sensing in the MDDNMR and NMRpipe software (Delaglio et al., 1995; Kazimierczuk and Orekhov, 2011; Orekhov and Jaravine, 2011). The final spectrum size was 922 real data points for the \(^1\)H dimension and 16,384 real data points for the \(^{13}\)C dimension. Analysis was performed using MetaboLab and pyGamma software was used in multiplet simulations (Smith et al., 1994). The methyl group of lactate was used to calibrate the chemical shift based on its assignment in the human metabolome database (Wishart et al., 2013).

**GC-MS**

Dried polar metabolites were purified as described for NMR spectroscopy. These were derivatised by incubating with 40 µL 2% methoxyamine hydrochloride (Sigma Aldrich, 226904) in pyridine (Thermo Fisher Scientific, 25104) at 60 °C for 1 h, followed by incubation with 60 µL \(N\)-methyl-\(N\)-\(N\)-tert-butyldimethylsilyl trifluoroacetamide with 1% \(t\)-\(tert\)-butyldimethylchlorosilane (MTBSTFA with 1% \(t\)-BDMS) at 60 °C for 1 h.

GC-MS analysis was performed using an Agilent 6890GC in combination with an Agilent 5975C MS. The MS was operated under electron impact ionization at 70 eV with the source held at 230 °C and the quadrupole at 150 °C. Helium was used as the carrier gas and maintained at a flow rate of 1 mL/min. 1 µL of derivatised sample was injected (splitless) with an inlet temperature of 280 °C on to a Rxi-5MS column (Restek) The oven temperature was held at 100 °C for 1 min then increased at a rate of 5 °C/min up to a maximum temperature of
330 °C. Ions were detected using selected ion monitoring (SIM) mode as previously described (Battello et al., 2016). MetaboliteDetector software was used to correct for the natural isotope distribution and to determine the mass isotopomer distribution (MID) (Hiller et al., 2009).

**DNA hydroxymethylation immunoprecipitation and sequencing (hmeDIP-sequencing)**

DNA was purified using the Monarch® Genomic DNA Purification kit (New England BioLabs, T3010S). DNA immunoprecipitation and sequencing was performed as previously described, using the Ion Proton platform (Thomson et al., 2015), with the addition of an IgG control (Merck, 12-370). We validated the DNA immunoprecipitation protocol on Roche LightCycler 480 (Roche Diagnostics Ltd, Switzerland), using the primer sets described in Table S3. We sequenced three biological replicates per group. A mean read length of 137-147 base pairs and 21,130,039 - 31,693,844 reads per sample was achieved. Reads were aligned to the hg19 genome using Torrent Suite v5.2.0. Aligned reads were sorted using SAMtools, before calling peaks using MACS2 (v. 2.1.1) -f BAM --broad --broad-cutoff 0.05 -B -g hs, over corresponding inputs (Zhang et al., 2008). To detect differentially hydroxymethylated regions (DHRs), we used Diffbind with DESeq2 (Stark and Brown). For Diffbind analysis, data were normalised to a pooled input for each group and an IgG control. DHMRs were assigned to genes and other genomic features using the HOMER (v. 4.8; hg19) annotatePeaks tools (Heinz et al., 2010). For candidate hmeDIP analysis, the concentration of each sample was extrapolated from a standard curve of arbitrary concentrations and normalised to 10% input. Regions of interest were identified from the hmeDIP-sequencing dataset. Primers were designed using the NCBI primer-BLAST software (Table S2). Data are available through the Gene Expression Omnibus (GSE144955). Sliding window profiles and heatmaps were generated using deepTools (Ramírez et al., 2014), using the plotProfile and plotHeatmap functions, respectively, with blacklisted regions subtracted.
Cells were stained with a cell painter assay, adapted from Lyall et al and Bray et al (Bray et al., 2016; Lyall et al., 2018). Cells were fixed with 50 μL/well 4% (wt/vol) paraformaldehyde (Electron Microscopy Sciences, 15710-S) for 15 minutes at room temperature. For permeabilisation, cells were incubated in 0.1% Triton X-100 (Sigma-Aldrich, T8787) in PBS for 15 minutes at room temperature. For lipid droplet analysis, cells were then stained with a combination of NucBlue Live ReadyProbes® Reagent (2 drops/mL) (Molecular Probes, R37605), HCS CellMask™ Red (2 μL/10 mL) (Invitrogen, H32712), and BODIPY™ 493/503 (1:1000) (Life Sciences, D3922), as per the manufacturer’s instructions. Following staining, images were acquired using an Operetta High Content Analysis microscope (Perkin Elmer, Buckinghamshire, UK). Lipid droplet morphology was analysed as previously described (Lyall et al., 2018).

**Statistical analysis**

All statistical analyses were performed using Graph Prism Version 8.0 for Windows or macOS, GraphPad Software, La Jolla California USA, www.graphpad.com. Normality of data distribution was measured using the Shapiro-Wilks test. Where indicated, data were analysed by unpaired Student’s t-test, Mann-Whitney test, one-way analysis of variance (ANOVA) or two-way ANOVA. Data were considered to be significant where $p < 0.05$. 
References

Andrews, S. FastQC: a quality control tool for high throughput sequence data.

Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J.R., Maciejewski, A., and Wishart, D.S. (2016). Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44, W147–W153.

Battel, N., Zimmer, A.D., Goebel, C., Dong, X., Behrmann, I., Haan, C., Hiller, K., and Wegner, A. (2016). The role of HIF-1 in oncostatin M-dependent metabolic reprogramming of hepatic cells. Cancer Metab. 4, 3.

Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120.

Boutagy, N.E., Pyne, E., Rogers, G.W., Ali, M., Hulver, M.W., and Frisard, M.I. (2015). Isolation of mitochondria from minimal quantities of mouse skeletal muscle for high throughput microplate respiratory measurements. J. Vis. Exp. 2015.

Bray, M.A., Singh, S., Han, H., Davis, C.T., Borgeson, B., Hartland, C., Kost-Alimova, M., Gustafsdottir, S.M., Gibson, C.C., and Carpenter, A.E. (2016). Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757–1774.

Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995). NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293.

Dobin, A., and Gingeras, T.R. (2015). Mapping RNA-seq Reads with STAR. Curr. Protoc. Bioinforma. 51, 11.14.1-11.14.19.

Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. Mol. Cell 38, 576–589.

Hiller, K., Hangebrauk, J., Jäger, C., Spura, J., Schreiber, K., and Schomburg, D. (2009). Metabolite detector: Comprehensive analysis tool for targeted and nontargeted GC/MS
based metabolome analysis. Anal. Chem. 81, 3429–3439.

Hollinshead, K.E.R., Munford, H., Eales, K.L., Bardella, C., Li, C., Escribano-Gonzalez, C.,

Thakker, A., Nonnenmacher, Y., Kluckova, K., Jeeves, M., et al. (2018). Oncogenic IDH1
Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance
of Mitochondrial Redox Homeostasis. Cell Rep. 22, 3107–3114.

Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment tools:
Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res.
37, 1–13.

Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57.

Kanehisa, M. (2019). Toward understanding the origin and evolution of cellular organisms.
Protein Sci. 28, 1947–1951.

Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res. 28, 27–30.

Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K., and Tanabe, M. (2019). New approach
for understanding genome variations in KEGG. Nucleic Acids Res. 47, D590–D595.

Kazimierczuk, K., and Orekhov, V.Y. (2011). Accelerated NMR spectroscopy by using
compressed sensing. Angew. Chemie - Int. Ed. 50, 5556–5559.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.

Ludwig, C., and Günther, U.L. (2011). MetaboLab - advanced NMR data processing and
analysis for metabolomics. BMC Bioinformatics 12, 366.

Lyall, M.J., Cartier, J., Thomson, J.P., Cameron, K., Meseguer-Ripolles, J., O'Duibhir, E.,
Szkolnicka, D., Villarin, B.L., Wang, Y., Blanco, G.R., et al. (2018). Modelling non-alcoholic
fatty liver disease in human hepatocyte-like cells. Philos. Trans. R. Soc. B Biol. Sci. 373,
20170362.

Orekhov, V.Y., and Jaravine, V.A. (2011). Analysis of non-uniformly sampled spectra with
multi-dimensional decomposition. Prog. Nucl. Magn. Reson. Spectrosc. 59, 271–292.
Orellana, E., and Kasinski, A. (2016). Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation. Bio-Protocol 6.

Ramírez, F., Dündar, F., Diehl, S., Grüning, B.A., and Manke, T. (2014). DeepTools: A flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187-91.

Short, K.R., Bigelow, M.L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakaimal, S., and Nair, K.S. (2005). Decline in skeletal muscle mitochondrial function with aging in humans. Proc. Natl. Acad. Sci. U. S. A. 102, 5618–5623.

Smith, S.A., Levante, T.O., Meier, B.H., and Ernst, R.R. (1994). Computer Simulations in Magnetic Resonance. An Object-Oriented Programming Approach. J. Magn. Reson. Ser. A 106, 75–105.

Stark, R., and Brown, G. Differential Binding Analysis of ChIP-Seq Peak Data.

Thomson, J.P., Fawkes, A., Ottaviano, R., Hunter, J.M., Shukla, R., Mjoseng, H.K., Clark, R., Coutts, A., Murphy, L., and Meehan, R.R. (2015). DNA immunoprecipitation semiconductor sequencing (DIP-SC-seq) as a rapid method to generate genome wide epigenetic signatures. Sci. Rep. 5, 9778.

Wang, Y., Alhaque, S., Cameron, K., Meseguer-Ripolles, J., Lucendo-Villarin, B., Rashidi, H., and Hay, D.C. (2017). Defined and scalable generation of hepatocyte-like cells from human pluripotent stem cells. J. Vis. Exp. e55355–e55355.

Wishart, D.S., Jewison, T., Guo, A.C., Wilson, M., Knox, C., Liu, Y., Djouroubou, Y., Mandal, R., Aziat, F., Dong, E., et al. (2013). HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 41, D801-7.

Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nussbaum, C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137.

(2018). Picard Tools - By Broad Institute.